Foy and Mandrola Discuss AF, AF-Ablation, Sham-controls, Evidence Translation and Heterogenous Treatment Effects
Sensible Medicine
SEPTEMBER 19, 2023
This week, I talk with Andrew Foy, who is an academic cardiologist at Penn State University in Hershey, PA. Andrew is one of the smartest voices in medicine today. We start with the REMEDIAL trial, published recently in JAMA. Ablation vs Meds. Primary endpoint—depression and anxiety. One of the main issues was the control arm—namely that there was no sham control.
Let's personalize your content